Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus

Meera Ramanujam, Xiaobo Wang, Weiqing Huang, Lena Schiffer, Christine Grimaldi, Alla Akkerman, Betty Diamond, Michael P. Madaio, Anne Davidson

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

B cell-activating factor belonging to the TNF family (BAFF) blockade prevents the onset of disease in systemic lupus erythematosus (SLE)-prone NZB/NZW F1 mice. To determine the mechanism of this effect, we administered a short course of TACI-Ig with and without six doses of CTLA4-Ig to 18- to 20-wk-old NZB/NZW F1 mice and evaluated the effect on B and T cell subsets and on anti-dsDNA Ab-producing B cells. Even a brief exposure to TACI-Ig had a beneficial effect on murine SLE; CTLA4-Ig potentiated this effect. The combination of TACI-Ig and CTLA4-Ig resulted in a temporary decrease in serum IgG levels. However, after cessation of treatment, high titers of IgG anti-dsDNA Abs appeared in the serum and IgG Abs deposited in the kidneys. Despite the appearance of pathogenic autoantibodies, the onset of proteinuria was markedly delayed; this was associated with prolonged depletion of B cells past the T1 stage, a decrease in the size of the spleen and lymph nodes, and a decrease in the absolute number of activated and memory CD4+ T cells. TACI-Ig treatment normalized serum levels of IgM that are markedly elevated in NZB/W F1 mice; this appeared to be due to a prolonged effect on the ability of the splenic microenvironment to support short-lived IgM plasma cells. Finally, a short course of combination TACI-Ig and CTLA4-Ig prolonged life and even reversed proteinuria in aged NZB/W F1 mice, suggesting that BAFF blockade may be an effective therapeutic strategy for active SLE.

Original languageEnglish (US)
Pages (from-to)3524-3534
Number of pages11
JournalJournal of Immunology
Volume173
Issue number5
DOIs
StatePublished - Sep 1 2004

Fingerprint

Systemic Lupus Erythematosus
Ligands
Calcium
Proteinuria
Immunoglobulin M
B-Lymphocytes
Immunoglobulin G
Serum
B-Cell Activating Factor
B-Lymphocyte Subsets
Withholding Treatment
T-Lymphocyte Subsets
Plasma Cells
Autoantibodies
Spleen
Lymph Nodes
TACI receptor-IgG Fc fragment fusion protein
T-Lymphocytes
Kidney
Abatacept

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. / Ramanujam, Meera; Wang, Xiaobo; Huang, Weiqing; Schiffer, Lena; Grimaldi, Christine; Akkerman, Alla; Diamond, Betty; Madaio, Michael P.; Davidson, Anne.

In: Journal of Immunology, Vol. 173, No. 5, 01.09.2004, p. 3524-3534.

Research output: Contribution to journalArticle

Ramanujam, M, Wang, X, Huang, W, Schiffer, L, Grimaldi, C, Akkerman, A, Diamond, B, Madaio, MP & Davidson, A 2004, 'Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus', Journal of Immunology, vol. 173, no. 5, pp. 3524-3534. https://doi.org/10.4049/jimmunol.173.5.3524
Ramanujam, Meera ; Wang, Xiaobo ; Huang, Weiqing ; Schiffer, Lena ; Grimaldi, Christine ; Akkerman, Alla ; Diamond, Betty ; Madaio, Michael P. ; Davidson, Anne. / Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. In: Journal of Immunology. 2004 ; Vol. 173, No. 5. pp. 3524-3534.
@article{8b742fea855c4ddd80919f090f5f20bb,
title = "Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus",
abstract = "B cell-activating factor belonging to the TNF family (BAFF) blockade prevents the onset of disease in systemic lupus erythematosus (SLE)-prone NZB/NZW F1 mice. To determine the mechanism of this effect, we administered a short course of TACI-Ig with and without six doses of CTLA4-Ig to 18- to 20-wk-old NZB/NZW F1 mice and evaluated the effect on B and T cell subsets and on anti-dsDNA Ab-producing B cells. Even a brief exposure to TACI-Ig had a beneficial effect on murine SLE; CTLA4-Ig potentiated this effect. The combination of TACI-Ig and CTLA4-Ig resulted in a temporary decrease in serum IgG levels. However, after cessation of treatment, high titers of IgG anti-dsDNA Abs appeared in the serum and IgG Abs deposited in the kidneys. Despite the appearance of pathogenic autoantibodies, the onset of proteinuria was markedly delayed; this was associated with prolonged depletion of B cells past the T1 stage, a decrease in the size of the spleen and lymph nodes, and a decrease in the absolute number of activated and memory CD4+ T cells. TACI-Ig treatment normalized serum levels of IgM that are markedly elevated in NZB/W F1 mice; this appeared to be due to a prolonged effect on the ability of the splenic microenvironment to support short-lived IgM plasma cells. Finally, a short course of combination TACI-Ig and CTLA4-Ig prolonged life and even reversed proteinuria in aged NZB/W F1 mice, suggesting that BAFF blockade may be an effective therapeutic strategy for active SLE.",
author = "Meera Ramanujam and Xiaobo Wang and Weiqing Huang and Lena Schiffer and Christine Grimaldi and Alla Akkerman and Betty Diamond and Madaio, {Michael P.} and Anne Davidson",
year = "2004",
month = "9",
day = "1",
doi = "10.4049/jimmunol.173.5.3524",
language = "English (US)",
volume = "173",
pages = "3524--3534",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "5",

}

TY - JOUR

T1 - Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus

AU - Ramanujam, Meera

AU - Wang, Xiaobo

AU - Huang, Weiqing

AU - Schiffer, Lena

AU - Grimaldi, Christine

AU - Akkerman, Alla

AU - Diamond, Betty

AU - Madaio, Michael P.

AU - Davidson, Anne

PY - 2004/9/1

Y1 - 2004/9/1

N2 - B cell-activating factor belonging to the TNF family (BAFF) blockade prevents the onset of disease in systemic lupus erythematosus (SLE)-prone NZB/NZW F1 mice. To determine the mechanism of this effect, we administered a short course of TACI-Ig with and without six doses of CTLA4-Ig to 18- to 20-wk-old NZB/NZW F1 mice and evaluated the effect on B and T cell subsets and on anti-dsDNA Ab-producing B cells. Even a brief exposure to TACI-Ig had a beneficial effect on murine SLE; CTLA4-Ig potentiated this effect. The combination of TACI-Ig and CTLA4-Ig resulted in a temporary decrease in serum IgG levels. However, after cessation of treatment, high titers of IgG anti-dsDNA Abs appeared in the serum and IgG Abs deposited in the kidneys. Despite the appearance of pathogenic autoantibodies, the onset of proteinuria was markedly delayed; this was associated with prolonged depletion of B cells past the T1 stage, a decrease in the size of the spleen and lymph nodes, and a decrease in the absolute number of activated and memory CD4+ T cells. TACI-Ig treatment normalized serum levels of IgM that are markedly elevated in NZB/W F1 mice; this appeared to be due to a prolonged effect on the ability of the splenic microenvironment to support short-lived IgM plasma cells. Finally, a short course of combination TACI-Ig and CTLA4-Ig prolonged life and even reversed proteinuria in aged NZB/W F1 mice, suggesting that BAFF blockade may be an effective therapeutic strategy for active SLE.

AB - B cell-activating factor belonging to the TNF family (BAFF) blockade prevents the onset of disease in systemic lupus erythematosus (SLE)-prone NZB/NZW F1 mice. To determine the mechanism of this effect, we administered a short course of TACI-Ig with and without six doses of CTLA4-Ig to 18- to 20-wk-old NZB/NZW F1 mice and evaluated the effect on B and T cell subsets and on anti-dsDNA Ab-producing B cells. Even a brief exposure to TACI-Ig had a beneficial effect on murine SLE; CTLA4-Ig potentiated this effect. The combination of TACI-Ig and CTLA4-Ig resulted in a temporary decrease in serum IgG levels. However, after cessation of treatment, high titers of IgG anti-dsDNA Abs appeared in the serum and IgG Abs deposited in the kidneys. Despite the appearance of pathogenic autoantibodies, the onset of proteinuria was markedly delayed; this was associated with prolonged depletion of B cells past the T1 stage, a decrease in the size of the spleen and lymph nodes, and a decrease in the absolute number of activated and memory CD4+ T cells. TACI-Ig treatment normalized serum levels of IgM that are markedly elevated in NZB/W F1 mice; this appeared to be due to a prolonged effect on the ability of the splenic microenvironment to support short-lived IgM plasma cells. Finally, a short course of combination TACI-Ig and CTLA4-Ig prolonged life and even reversed proteinuria in aged NZB/W F1 mice, suggesting that BAFF blockade may be an effective therapeutic strategy for active SLE.

UR - http://www.scopus.com/inward/record.url?scp=4344597627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344597627&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.173.5.3524

DO - 10.4049/jimmunol.173.5.3524

M3 - Article

C2 - 15322217

AN - SCOPUS:4344597627

VL - 173

SP - 3524

EP - 3534

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 5

ER -